Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2014 - Market Size, Share, Trends

Description

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2014

Summary

Global Markets Directs, Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2014, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS)s therapeutic pipeline.

View Full Report At: http://www.marketresearchreports.biz/analysis/235155

This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/235155

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products

Related Reports

Bronchiectasis - Pipeline Review, H2 2014

View Full Report At: http://www.marketresearchreports.biz/analysis/220017

This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA)

Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/220017

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2014

View Full Report At: http://www.marketresearchreports.biz/analysis/220018

This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates.

Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/220018

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings.

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz